

APPROVED

By Jean Gildner at 2:52 pm, Jul 19, 2016

From: Gildner, Jean
To: maquilera@vcel.com
Bcc: [Kenney, James](#); [Thomas, John](#)
Subject: BLA125603 IR regarding (b) (4) Validation
Date: Wednesday, June 29, 2016 2:23:00 PM
Attachments: [201606229_STN 125603 2ed Information Request for \(b\) \(4\) _method.doc](#)

Dear Margarita,

Please find attached the IR regarding the (b) (4) discussed by Dr. Kenney today at our tcon. If you have any additional questions please feel free to contact me. Please acknowledge receipt of this email.

Sincerely, Jean

Jean F. Gildner MSHS, MT (ASCP), CQA (ASQ)

Regulatory Project Manager
FDA/CBER/OCTGT
10903 New Hampshire Avenue
Bldg. 71, RM. 5222
Silver Spring, MD 20993-0002
Phone: (240) 402-8296
Fax: (301) 595-1303
jean.gildner@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.